Design, synthesis and investigation on the structure-activity relationships of N-substituted 2-aminothiazole derivatives as antitubercular agents

被引:59
作者
Pieroni, Marco [1 ]
Wan, Baojie [2 ]
Cho, Sanghyun [2 ]
Franzblau, Scott G. [2 ]
Costantino, Gabriele [1 ]
机构
[1] Univ Parma, Dipartimento Farm, I-43124 Parma, Italy
[2] Univ Illinois, Coll Pharm, Inst TB Res, Chicago, IL 60612 USA
关键词
Tuberculosis; Medicinal chemistry; Resistance; Drug discovery; 2-Aminothiazoles; NONREPLICATING MYCOBACTERIUM-TUBERCULOSIS; DRUG-RESISTANT TUBERCULOSIS; BIOLOGICAL EVALUATION; GROWTH-INHIBITORS; POTENT; ESTERS; SERIES; ASSAY;
D O I
10.1016/j.ejmech.2013.11.007
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Tuberculosis (TB) is one of the deadliest infectious diseases of all times, and its recent resurgence is a supreme matter of concern. Co-infection with HIV and, in particular, the continuous isolation of new resistant strains, makes the discovery of novel anti-TB agents a strategic priority. The research of novel agents should be driven by the accessibility of the synthetic procedure and, in particular, by the lack of cross-resistance with the drugs already marketed. Moreover, in order to shorten the duration of the therapy, and therefore decrease the rate of resistance, these molecules should be active also against the nonreplicating persistent form (NRP-TB) of the infection. The availability of an in-house small library of compounds prompted us to investigate their anti-TB activity. Two compounds, embodying a 2-aminothiazole scaffold, were found to possess a certain inhibitory activity toward Mycobacterium tuberculosis H(37)Rv, and therefore a medicinal chemistry campaign was initiated in order to increase the activity of the hit compounds and, especially, construct a plausible body of structure activity relationships. The potency of the hit compound was successfully improved, and, much more importantly, some of the molecules synthesized were found to be active toward the persistent phenotype, and, also, toward a panel of resistant strains. These findings encourage further investigations around this interesting antitubercular chemotype. (C) 2013 Elsevier Masson SAS. All rights reserved.
引用
收藏
页码:26 / 34
页数:9
相关论文
共 42 条
  • [21] Preclinical testing of the nitroimidazopyran PA-824 for activity against Mycobacterium tuberculosis in a series of in vitro and in vivo models
    Lenaerts, AJ
    Gruppo, V
    Marietta, KS
    Johnson, CM
    Driscoll, DK
    Tompkins, NM
    Rose, JD
    Reynolds, RC
    Orme, IM
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2005, 49 (06) : 2294 - 2301
  • [22] Derivatives of 3-Isoxazolecarboxylic Acid Esters - A Potent and Selective Compound Class against Replicating and Nonreplicating Mycobacterium tuberculosis
    Lilienkampf, Annamaria
    Pieroni, Marco
    Franzblau, Scott G.
    Bishai, William R.
    Kozikowski, Alan P.
    [J]. CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2012, 12 (07) : 729 - 734
  • [23] Rational Design of 5-Phenyl-3-isoxazolecarboxylic Acid Ethyl Esters as Growth Inhibitors of Mycobacterium tuberculosis. A Potent and Selective Series for Further Drug Development
    Lilienkampf, Annamaria
    Pieroni, Marco
    Wan, Baojie
    Wang, Yuehong
    Franzblau, Scott G.
    Kozikowski, Alan P.
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 2010, 53 (02) : 678 - 688
  • [24] From Serendipity to Rational Antituberculosis Drug Discovery of Mefloquine-Isoxazole Carboxylic Acid Esters
    Mao, Jialin
    Yuan, Hai
    Wang, Yuehong
    Wan, Baojie
    Pieroni, Marco
    Huang, Qingqing
    van Breemen, Richard B.
    Kozikowski, Alan P.
    Franzblau, Scott G.
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 2009, 52 (22) : 6966 - 6978
  • [25] McKinney JD, 1998, BIOMED RES REP, P51
  • [26] MIGLIORI GB, 2007, EURO SURVEILL, V12
  • [27] The need for new drugs against tuberculosis - Obstacles, opportunities, and next steps
    O'Brien, RJ
    Nunn, PP
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2001, 163 (05) : 1055 - 1058
  • [28] Preliminary Structure-Activity Relationships and Biological Evaluation of Novel Antitubercular Indolecarboxamide Derivatives Against Drug-Susceptible and Drug-Resistant Mycobacterium tuberculosis Strains
    Onajole, Oluseye K.
    Pieroni, Marco
    Tipparaju, Suresh K.
    Lun, Shichun
    Stec, Jozef
    Chen, Gang
    Gunosewoyo, Hendra
    Guo, Haidan
    Ammerman, Nicole C.
    Bishai, William R.
    Kozikowski, Alan P.
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 2013, 56 (10) : 4093 - 4103
  • [29] Directly observed therapy (DOT) for tuberculosis: why, when, how and if?
    Ormerod, LP
    [J]. THORAX, 1999, 54 : S42 - S45
  • [30] Synthesis and Structure-Activity Relationships of Lansine Analogues as Antileishmanial Agents
    Pieroni, Marco
    Girmay, Sisay
    Sun, Dianqing
    Sahu, Rajnish
    Tekwani, Babu L.
    Tan, Ghee T.
    [J]. CHEMMEDCHEM, 2012, 7 (11) : 1895 - 1900